CA2543986C - Inhibiteurs de recapture de la noradrenaline et methodes d'utilisation connexes - Google Patents

Inhibiteurs de recapture de la noradrenaline et methodes d'utilisation connexes Download PDF

Info

Publication number: CA2543986C
Authority: CA; Canada
Prior art keywords: reboxetine; disorder; norepinephrine; reuptake; disorders
Prior art date: 1999-07-01
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA002543986A

Other languages

English (en)

Other versions

CA2543986A1 (fr

Inventor

Erik H.F. Wong

Saeeduddin Ahmed

Robert Clyde Marshall

Robert Mcarthur

Duncan P. Taylor

Lars Birgerson

Pasquale Cetera

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pharmacia and Upjohn Co

Original Assignee

Pharmacia and Upjohn Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-01

Filing date

2000-06-22

Publication date

2009-03-03

2000-06-22 Application filed by Pharmacia and Upjohn Co filed Critical Pharmacia and Upjohn Co

2000-06-22 Priority to CA002643231A priority Critical patent/CA2643231A1/fr

2000-06-22 Priority claimed from CA002375908A external-priority patent/CA2375908C/fr

2001-01-11 Publication of CA2543986A1 publication Critical patent/CA2543986A1/fr

2009-03-03 Application granted granted Critical

2009-03-03 Publication of CA2543986C publication Critical patent/CA2543986C/fr

2020-06-22 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

238000000034 method Methods 0.000 title abstract description 32
239000002767 noradrenalin uptake inhibitor Substances 0.000 title description 16
229940127221 norepinephrine reuptake inhibitor Drugs 0.000 title description 7
CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 claims abstract description 106
229960003770 reboxetine Drugs 0.000 claims abstract description 88
239000003814 drug Substances 0.000 claims abstract description 23
238000004519 manufacturing process Methods 0.000 claims abstract description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 48
208000035475 disorder Diseases 0.000 claims description 41
238000011282 treatment Methods 0.000 claims description 27
208000027520 Somatoform disease Diseases 0.000 claims description 20
150000003839 salts Chemical class 0.000 claims description 18
208000019695 Migraine disease Diseases 0.000 claims description 13
206010027603 Migraine headaches Diseases 0.000 claims description 12
206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 9
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 9
208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 9
208000001640 Fibromyalgia Diseases 0.000 claims description 7
208000033808 peripheral neuropathy Diseases 0.000 claims description 6
201000001916 Hypochondriasis Diseases 0.000 claims description 5
208000022266 body dysmorphic disease Diseases 0.000 claims description 5
208000012839 conversion disease Diseases 0.000 claims description 5
208000027753 pain disease Diseases 0.000 claims description 5
208000033039 Somatisation disease Diseases 0.000 claims description 4
208000016994 somatization disease Diseases 0.000 claims description 4
238000011321 prophylaxis Methods 0.000 claims description 2
239000000203 mixture Substances 0.000 abstract description 81
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract description 62
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract description 55
229960002748 norepinephrine Drugs 0.000 abstract description 55
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract description 55
150000001875 compounds Chemical class 0.000 abstract description 32
230000002401 inhibitory effect Effects 0.000 abstract description 30
229940076279 serotonin Drugs 0.000 abstract description 29
230000000144 pharmacologic effect Effects 0.000 abstract description 17
208000020016 psychiatric disease Diseases 0.000 abstract description 14
230000008901 benefit Effects 0.000 abstract description 10
238000002360 preparation method Methods 0.000 abstract description 5
230000001225 therapeutic effect Effects 0.000 abstract description 4
241000282412 Homo Species 0.000 abstract description 2
CBQGYUDMJHNJBX-OALUTQOASA-N (2S)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine Chemical compound CCOC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 CBQGYUDMJHNJBX-OALUTQOASA-N 0.000 description 62
230000000694 effects Effects 0.000 description 35
230000005764 inhibitory process Effects 0.000 description 18
230000000966 norepinephrine reuptake Effects 0.000 description 16
230000002411 adverse Effects 0.000 description 15
230000000697 serotonin reuptake Effects 0.000 description 14
206010066218 Stress Urinary Incontinence Diseases 0.000 description 12
239000000935 antidepressant agent Substances 0.000 description 12
229940079593 drug Drugs 0.000 description 12
102000005962 receptors Human genes 0.000 description 11
108020003175 receptors Proteins 0.000 description 11
208000022170 stress incontinence Diseases 0.000 description 11
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 10
229940005513 antidepressants Drugs 0.000 description 10
-1 carpoate Chemical compound 0.000 description 9
208000011688 Generalised anxiety disease Diseases 0.000 description 8
208000012902 Nervous system disease Diseases 0.000 description 8
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
208000029364 generalized anxiety disease Diseases 0.000 description 8
230000003389 potentiating effect Effects 0.000 description 8
208000019901 Anxiety disease Diseases 0.000 description 7
206010002942 Apathy Diseases 0.000 description 7
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 7
239000004480 active ingredient Substances 0.000 description 7
230000037328 acute stress Effects 0.000 description 7
230000036506 anxiety Effects 0.000 description 7
208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 7
230000027455 binding Effects 0.000 description 7
230000037326 chronic stress Effects 0.000 description 7
201000010099 disease Diseases 0.000 description 7
208000024732 dysthymic disease Diseases 0.000 description 7
239000002858 neurotransmitter agent Substances 0.000 description 7
239000008194 pharmaceutical composition Substances 0.000 description 7
208000028173 post-traumatic stress disease Diseases 0.000 description 7
230000002265 prevention Effects 0.000 description 7
208000024891 symptom Diseases 0.000 description 7
208000011580 syndromic disease Diseases 0.000 description 7
206010006550 Bulimia nervosa Diseases 0.000 description 6
206010012374 Depressed mood Diseases 0.000 description 6
206010057852 Nicotine dependence Diseases 0.000 description 6
208000027030 Premenstrual dysphoric disease Diseases 0.000 description 6
208000028017 Psychotic disease Diseases 0.000 description 6
208000025569 Tobacco Use disease Diseases 0.000 description 6
208000012826 adjustment disease Diseases 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
239000003112 inhibitor Substances 0.000 description 6
230000004044 response Effects 0.000 description 6
239000003826 tablet Substances 0.000 description 6
HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 5
206010021639 Incontinence Diseases 0.000 description 5
206010026749 Mania Diseases 0.000 description 5
206010053236 Mixed incontinence Diseases 0.000 description 5
208000008589 Obesity Diseases 0.000 description 5
208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 5
229940123445 Tricyclic antidepressant Drugs 0.000 description 5
206010048010 Withdrawal syndrome Diseases 0.000 description 5
229960003914 desipramine Drugs 0.000 description 5
239000007788 liquid Substances 0.000 description 5
238000002483 medication Methods 0.000 description 5
235000020824 obesity Nutrition 0.000 description 5
239000000825 pharmaceutical preparation Substances 0.000 description 5
230000009467 reduction Effects 0.000 description 5
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 5
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
239000003029 tricyclic antidepressant agent Substances 0.000 description 5
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
208000000103 Anorexia Nervosa Diseases 0.000 description 4
208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 description 4
208000020925 Bipolar disease Diseases 0.000 description 4
208000000094 Chronic Pain Diseases 0.000 description 4
208000020401 Depressive disease Diseases 0.000 description 4
208000020358 Learning disease Diseases 0.000 description 4
102000010909 Monoamine Oxidase Human genes 0.000 description 4
108010062431 Monoamine oxidase Proteins 0.000 description 4
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
208000025966 Neurological disease Diseases 0.000 description 4
208000002193 Pain Diseases 0.000 description 4
206010041250 Social phobia Diseases 0.000 description 4
239000002253 acid Substances 0.000 description 4
150000007513 acids Chemical class 0.000 description 4
230000001430 anti-depressive effect Effects 0.000 description 4
238000003556 assay Methods 0.000 description 4
239000002585 base Substances 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
239000002775 capsule Substances 0.000 description 4
208000026725 cyclothymic disease Diseases 0.000 description 4
208000002173 dizziness Diseases 0.000 description 4
229960003638 dopamine Drugs 0.000 description 4
201000003723 learning disability Diseases 0.000 description 4
208000024196 oppositional defiant disease Diseases 0.000 description 4
208000019906 panic disease Diseases 0.000 description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
208000012672 seasonal affective disease Diseases 0.000 description 4
208000019116 sleep disease Diseases 0.000 description 4
208000012217 specific developmental disease Diseases 0.000 description 4
238000012360 testing method Methods 0.000 description 4
208000016686 tic disease Diseases 0.000 description 4
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 3
208000024827 Alzheimer disease Diseases 0.000 description 3
208000027691 Conduct disease Diseases 0.000 description 3
208000008967 Enuresis Diseases 0.000 description 3
208000018522 Gastrointestinal disease Diseases 0.000 description 3
206010019233 Headaches Diseases 0.000 description 3
206010033307 Overweight Diseases 0.000 description 3
206010036618 Premenstrual syndrome Diseases 0.000 description 3
208000020190 Schizoaffective and schizophreniform disease Diseases 0.000 description 3
201000001880 Sexual dysfunction Diseases 0.000 description 3
208000000323 Tourette Syndrome Diseases 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
230000001149 cognitive effect Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
239000003085 diluting agent Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
230000008406 drug-drug interaction Effects 0.000 description 3
230000001544 dysphoric effect Effects 0.000 description 3
229960002464 fluoxetine Drugs 0.000 description 3
239000008187 granular material Substances 0.000 description 3
231100000869 headache Toxicity 0.000 description 3
230000002631 hypothermal effect Effects 0.000 description 3
230000035987 intoxication Effects 0.000 description 3
231100000566 intoxication Toxicity 0.000 description 3
230000029849 luteinization Effects 0.000 description 3
229960004090 maprotiline Drugs 0.000 description 3
QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 3
239000000463 material Substances 0.000 description 3
230000036651 mood Effects 0.000 description 3
201000003631 narcolepsy Diseases 0.000 description 3
210000002569 neuron Anatomy 0.000 description 3
FDXQKWSTUZCCTM-UHFFFAOYSA-N oxaprotiline Chemical compound C12=CC=CC=C2C2(CC(O)CNC)C3=CC=CC=C3C1CC2 FDXQKWSTUZCCTM-UHFFFAOYSA-N 0.000 description 3
239000000843 powder Substances 0.000 description 3
201000000980 schizophrenia Diseases 0.000 description 3
231100000872 sexual dysfunction Toxicity 0.000 description 3
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
IVWWFWFVSWOTLP-YVZVNANGSA-N (3'as,4r,7'as)-2,2,2',2'-tetramethylspiro[1,3-dioxolane-4,6'-4,7a-dihydro-3ah-[1,3]dioxolo[4,5-c]pyran]-7'-one Chemical compound C([C@@H]1OC(O[C@@H]1C1=O)(C)C)O[C@]21COC(C)(C)O2 IVWWFWFVSWOTLP-YVZVNANGSA-N 0.000 description 2
CBQGYUDMJHNJBX-UHFFFAOYSA-N 2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine Chemical compound CCOC1=CC=CC=C1OC(C=1C=CC=CC=1)C1OCCNC1 CBQGYUDMJHNJBX-UHFFFAOYSA-N 0.000 description 2
ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 2
108060003345 Adrenergic Receptor Proteins 0.000 description 2
102000017910 Adrenergic receptor Human genes 0.000 description 2
208000007848 Alcoholism Diseases 0.000 description 2
206010011224 Cough Diseases 0.000 description 2
229930182843 D-Lactic acid Natural products 0.000 description 2
JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
102000004108 Neurotransmitter Receptors Human genes 0.000 description 2
108090000590 Neurotransmitter Receptors Proteins 0.000 description 2
208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
230000009471 action Effects 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000001078 anti-cholinergic effect Effects 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
206010005159 blepharospasm Diseases 0.000 description 2
230000000744 blepharospasm Effects 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000002490 cerebral effect Effects 0.000 description 2
238000000586 desensitisation Methods 0.000 description 2
230000002825 dopamine reuptake Effects 0.000 description 2
230000003828 downregulation Effects 0.000 description 2
238000006911 enzymatic reaction Methods 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000006870 function Effects 0.000 description 2
229960004801 imipramine Drugs 0.000 description 2
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 2
238000011534 incubation Methods 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
206010022437 insomnia Diseases 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
208000013433 lightheadedness Diseases 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
230000003340 mental effect Effects 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 2
229940098779 methanesulfonic acid Drugs 0.000 description 2
QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
229960003955 mianserin Drugs 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
230000008450 motivation Effects 0.000 description 2
238000000465 moulding Methods 0.000 description 2
229960002715 nicotine Drugs 0.000 description 2
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
230000002474 noradrenergic effect Effects 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
239000006187 pill Substances 0.000 description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
239000002287 radioligand Substances 0.000 description 2
QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 2
238000012552 review Methods 0.000 description 2
208000022610 schizoaffective disease Diseases 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000037317 transdermal delivery Effects 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 description 1
OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
206010003591 Ataxia Diseases 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
206010048610 Cardiotoxicity Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010010947 Coordination abnormal Diseases 0.000 description 1
101710095468 Cyclase Proteins 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
102000015554 Dopamine receptor Human genes 0.000 description 1
108050004812 Dopamine receptor Proteins 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
208000008454 Hyperhidrosis Diseases 0.000 description 1
206010020853 Hypertonic bladder Diseases 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 1
229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
208000009233 Morning Sickness Diseases 0.000 description 1
241000907681 Morpho Species 0.000 description 1
101100223893 Mycolicibacterium fortuitum sulI gene Proteins 0.000 description 1
208000009722 Overactive Urinary Bladder Diseases 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
206010037180 Psychiatric symptoms Diseases 0.000 description 1
WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
230000010799 Receptor Interactions Effects 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
241000978776 Senegalia senegal Species 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
208000001871 Tachycardia Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
208000000921 Urge Urinary Incontinence Diseases 0.000 description 1
206010046555 Urinary retention Diseases 0.000 description 1
206010047513 Vision blurred Diseases 0.000 description 1
208000034850 Vomiting in pregnancy Diseases 0.000 description 1
ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
YTIVTFGABIZHHX-UHFFFAOYSA-L acetylenedicarboxylate(2-) Chemical compound [O-]C(=O)C#CC([O-])=O YTIVTFGABIZHHX-UHFFFAOYSA-L 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
230000008503 anti depressant like effect Effects 0.000 description 1
230000000891 anti-reserpine Effects 0.000 description 1
VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 1
229960002430 atomoxetine Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
229940030611 beta-adrenergic blocking agent Drugs 0.000 description 1
230000000035 biogenic effect Effects 0.000 description 1
239000003181 biological factor Substances 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
231100000259 cardiotoxicity Toxicity 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
210000004289 cerebral ventricle Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000002131 composite material Substances 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
230000008602 contraction Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
210000005257 cortical tissue Anatomy 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
229940022769 d- lactic acid Drugs 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
NELSQLPTEWCHQW-UHFFFAOYSA-N fezolamine Chemical compound N=1N(CCCN(C)C)C=C(C=2C=CC=CC=2)C=1C1=CC=CC=C1 NELSQLPTEWCHQW-UHFFFAOYSA-N 0.000 description 1
229950000761 fezolamine Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000012458 free base Substances 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
KKLGDUSGQMHBPB-UHFFFAOYSA-N hex-2-ynedioic acid Chemical compound OC(=O)CCC#CC(O)=O KKLGDUSGQMHBPB-UHFFFAOYSA-N 0.000 description 1
230000000742 histaminergic effect Effects 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229960002672 isocarboxazid Drugs 0.000 description 1
208000028756 lack of coordination Diseases 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
238000005567 liquid scintillation counting Methods 0.000 description 1
229960002813 lofepramine Drugs 0.000 description 1
SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
125000005341 metaphosphate group Chemical group 0.000 description 1
IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
229940095102 methyl benzoate Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229960001785 mirtazapine Drugs 0.000 description 1
RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
230000003551 muscarinic effect Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000012154 norepinephrine uptake Effects 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
229940053544 other antidepressants in atc Drugs 0.000 description 1
208000020629 overactive bladder Diseases 0.000 description 1
229960002296 paroxetine Drugs 0.000 description 1
238000010827 pathological analysis Methods 0.000 description 1
239000008188 pellet Substances 0.000 description 1
229950009215 phenylbutanoic acid Drugs 0.000 description 1
HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229940068965 polysorbates Drugs 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
230000003518 presynaptic effect Effects 0.000 description 1
210000005215 presynaptic neuron Anatomy 0.000 description 1
239000000047 product Substances 0.000 description 1
KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
229960003712 propranolol Drugs 0.000 description 1
UORVCLMRJXCDCP-UHFFFAOYSA-M propynoate Chemical compound [O-]C(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-M 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000000611 regression analysis Methods 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229940116351 sebacate Drugs 0.000 description 1
CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
230000001624 sedative effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000013275 serotonin uptake Effects 0.000 description 1
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
229960002073 sertraline Drugs 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
230000005586 smoking cessation Effects 0.000 description 1
206010041232 sneezing Diseases 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
210000005070 sphincter Anatomy 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
TYFQFVWCELRYAO-UHFFFAOYSA-L suberate(2-) Chemical compound [O-]C(=O)CCCCCCC([O-])=O TYFQFVWCELRYAO-UHFFFAOYSA-L 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000035900 sweating Effects 0.000 description 1
230000000946 synaptic effect Effects 0.000 description 1
210000003568 synaptosome Anatomy 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000006794 tachycardia Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
231100000462 teratogen Toxicity 0.000 description 1
239000003439 teratogenic agent Substances 0.000 description 1
229960003433 thalidomide Drugs 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
238000003569 transporter assay Methods 0.000 description 1
229960003991 trazodone Drugs 0.000 description 1
PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
206010046494 urge incontinence Diseases 0.000 description 1
230000003202 urodynamic effect Effects 0.000 description 1
230000000980 vagolytic effect Effects 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229940071104 xylenesulfonate Drugs 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA002543986A 1999-07-01 2000-06-22 Inhibiteurs de recapture de la noradrenaline et methodes d'utilisation connexes Expired - Fee Related CA2543986C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA002643231A CA2643231A1 (fr)	1999-07-01	2000-06-22	Inhibiteurs de recapture de la noradrenaline et methodes d'utilisation connexes

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US14196899P	1999-07-01	1999-07-01
US60/141,968		1999-07-01
US14413199P	1999-07-16	1999-07-16
US60/144,131		1999-07-16
US15825699P	1999-10-06	1999-10-06
US60/158,256		1999-10-06
US17038199P	1999-12-13	1999-12-13
US60/170,381		1999-12-13
CA002375908A CA2375908C (fr)	1999-07-01	2000-06-22	Inhibiteurs de recaptage de noradrenaline hautement selectifs et leurs methodes d'utilisation

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002375908A Division CA2375908C (fr)	1999-07-01	2000-06-22	Inhibiteurs de recaptage de noradrenaline hautement selectifs et leurs methodes d'utilisation

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002643231A Division CA2643231A1 (fr)	1999-07-01	2000-06-22	Inhibiteurs de recapture de la noradrenaline et methodes d'utilisation connexes

Publications (2)

Publication Number	Publication Date
CA2543986A1 CA2543986A1 (fr)	2001-01-11
CA2543986C true CA2543986C (fr)	2009-03-03

Family

ID=36141768

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CA002532330A Expired - Fee Related CA2532330C (fr)	1999-07-01	2000-06-22	Inhibiteurs de recaptage de noradrenaline hautement selectifs et leurs methodes d'utilisation
CA002543986A Expired - Fee Related CA2543986C (fr)	1999-07-01	2000-06-22	Inhibiteurs de recapture de la noradrenaline et methodes d'utilisation connexes

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CA002532330A Expired - Fee Related CA2532330C (fr)	1999-07-01	2000-06-22	Inhibiteurs de recaptage de noradrenaline hautement selectifs et leurs methodes d'utilisation

Country Status (1)

Country	Link
CA (2)	CA2532330C (fr)

2000
- 2000-06-22 CA CA002532330A patent/CA2532330C/fr not_active Expired - Fee Related
- 2000-06-22 CA CA002543986A patent/CA2543986C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2543986A1 (fr)	2001-01-11
CA2532330A1 (fr)	2001-01-11
CA2532330C (fr)	2009-04-21

Legal Events

Date	Code	Title	Description
2006-05-05	EEER	Examination request
2010-06-22	MKLA	Lapsed

Publication	Publication Date	Title
CA2375908C (fr)	2006-05-30	Inhibiteurs de recaptage de noradrenaline hautement selectifs et leurs methodes d'utilisation
EP1500395A1 (fr)	2005-01-26	Reboxétine pour traiter les fibromyalgies et d'autres troubles somatoformes
CA2543986C (fr)	2009-03-03	Inhibiteurs de recapture de la noradrenaline et methodes d'utilisation connexes
NZ542816A (en)	2006-12-22	Optically pure (S.S) reboxetine in the treatment of conditions such as those involving addiction and TIC disorders in which inhibiting reuptake of norepinephrine (nor adrenaline) provides relief
NZ550213A (en)	2008-02-29	Use of racemic reboxetine for the treatment of chronic fatigue syndrome, fibromyalgia or another somatoform disorder, migraine headaches and peripheral neuropathy